

aap Implantate AG Corporate Presentation

8th DVFA Frühjahrskonferenz

Frankfurt am Main, May 8, 2017

Bruke Seyoum Alemu, CEO Marek Hahn, CFO



Safe Harbor Statement

Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Throughout today's discussion, we will attempt to present some important factors relating to our business that may affect our predictions.



Share Buyback

Partial distribution of proceeds from sale of *aap* Biomaterials

- aap's Management Board and Supervisory Board decided today to implement a share buyback within the next months in order to partially distribute proceeds from last year's sale of aap Biomaterials GmbH to shareholders
- Based on the current share price level of the *aap* share it is intended to purchase **up to 2.4 million** *aap* shares from the shareholders for a maximum total purchase price (including transaction costs) of **up to EUR 3.5 million**
- Further details of the share buyback, including the purchase price, will be determined and published by the Management Board within the next weeks
- If market circumstances or the share price development changes the Management Board reserves the right to adapt the conditions of the intended share buyback or refrain from it

aap Company Overview



German based international MedTech company
Development, manufacturing and marketing of trauma products for orthopaedics
Listed in Frankfurt, Germany, Prime standard (XETRA: AAQ)
Customers are hospitals, distributors and global companies worldwide
Sales 2016: EUR 10.5 million (continued operation) after

diverse strategic divestitures



Our Aspiration



Making trauma treatment better and cost-effective

Challenges in trauma

- Simplify implantation as well as explantation
- Prevent surgical site infections
- Avoid second operations

Our response to the challenges

Address the challenges through innovations and create a sustainable value for our clients (patients, surgeons, hospitals) as well as shareholders

Our Roadmap for Value Creation

Transformational roadmap

- Transformation through divestiture
- Transformation through innovation

Divestiture

- In the last years we have executed diverse divestitures to become a pure player in trauma
- The last and decisive divestiture was the sale of our biomaterials business (EV/recurring EBITDA: 9 times)
- Today *aap* is a pure trauma player

Innovation

- In the last years we have been developing exciting platform technologies to become a leading trauma company:
 - LOQTEQ[®] plating technology
 - Antimicrobial silver coating technology
 - Resorbable coated magnesium implants technology



Transformation Through Innovation Clear objectives

Clear innovation objectives

- Address unmet needs
- Enable differentiation
- Build strong intellectual property portfolio
- Ensure cost-effective technical feasibility
- Fulfil key market regulatory approvals
- Capture decent market size

Our core technologies LOQTEQ[®], Silver Coating and Resorbable Coated Magnesium Implants are based on these objectives.



Platform Technology – LOQTEQ Value based innovation

Market Need

Efficient and minimal invasive surgery

- Angular stable locking and compression
- High stability of screw-plate-connection
- As few surgical steps as possible
- Uncomplicated removal of the implant with little time exposure

Technology



Innovative Solution



First Application 2011



>90% indication coverage in mainstream trauma




Platform Technology – Silver Coating Value based innovation

Unmet Need


Infection prevention for medical devices

Surgical Site Infection (SSI)




Biofilm formed on an TiAl6V4 implant surface S. epidermidis ATCC 35984

Technology



Innovative Solution



First Application



Platform Technology – Magnesium Implants Value based innovation

Unmet Need

Biocompatible and biodegradable metal implants


Disadvantages of currently used metallic implants

- Need of second surgery for implant removal
- Stress shielding
- Inflammatory osteolysis caused by toxic titanium particles
- Interference in radiological studies

Technology




Innovative Solution



First Application





Preliminary Sales Q1/2017 and Guidance (in EUR million)

Preliminary Sales*	Q1/2017	Q1/2016	Change
Trauma	2.9	2.2	+30%
thereof North America and Europe	2.1	1.8	+16%
thereof RoW	0.8	0.4	+87%
Other (mainly discontinued activities)	0.2	0.3	-33%
Sales	3.1	2.5	+23%

*These preliminary results are based on management's initial analysis of operations for the period ended on 31 March 2017, and are therefore subject to change. *aap* plans to publish its final results for the first quarter of 2017 on 15 May 2017.

Guidance

FY/2017

- Sales: EUR 10.0 million EUR 13.0 million (FY/2016: EUR 10.5 million)
- EBITDA: EUR -6.5 million EUR -4.5 million (FY/2016: EUR -7.9 million)

Targeted annual growth in trauma in the next years of 20%



Financial Figures FY/2016 (in EUR million)

Capital Structure	FY/2016	FY/2015	Change
Total Assets	63.9	54.9	+16%
Equity Ratio	86%	73%	+18%

Value development	FY/2016	FY/2015	Change
Share of intangible assets in total assets	17%	19%	-11%
Freshness Index	26%	21%	+24%

Cash Structure	FY/2016	FY/2015	Change
Financial Liabilities (Interest bearing)	2.8	4.9	-43%
Net Cash	23.0	0.0	>+100%

Following the recent divestments aap is well funded with a sound balance sheet structure forming a solid basis for further growth.

Accelerated Path to Profitable Growth

aap Trauma

- Accelerated access to level-1 and -2 hospitals through substantial portfolio extension; today >90% indication coverage in mainstream trauma
- High growth momentum in Europe and North America through own sales organization
- Additional growth dynamic through portfolio extension to foot & ankle
- Additional distribution opportunity through partnerships with global companies

aap Silver

- Coating technology as a catalyst to own trauma portfolio
- Co-development projects and license deals with global medtech companies in trauma and nontrauma areas (cardio-vascular devices, dental implants, surgical instruments etc.)

Our goal is to achieve >20% EBITDA margins in 3 years

aap – Sum of the Parts




aap Trauma

- Strong IP, comprehensive portfolio
- Trauma sales 2016: ca. EUR 9 million; strong LOQTEQ[®] sales growth with CAGR 2011-2016 > 60%
- Valuation: Median EV/Sales of 4-6 in recent global transactions of pure trauma companies

aap Silver

- Technology addresses unmet need
- Strong IP, leading platform technology with a wide range of applications
- Valuation: external assessment by reputable consultancy firm on licensing opportunities shows huge value potential



The New *aap* – Pure Trauma Company Why invest in *aap*?

Comprehensive IP protected platform technologies

LOQTEQ[®] Technology, Silver Coating Technology, Resorbable Coated Magnesium Implants Technology

Comprehensive product portfolio

- CE, FDA and SFDA approved; indication coverage > 90% in mainstream trauma
- > Attractive for established markets, purchasing and hospital groups and tender business

Accelerated and profitable multiple growth opportunities

- Strong pipeline with continuous launch of new innovative products
- Competitive proposition to be active in the three fastest-growing segments of orthopaedics
- > Sales focus on established markets: Europe and North America
- Global partnerships with industry leaders
- > Technology and product portfolio attractive for global partners
 - Enabling additional revenue streams and business opportunities

Growth financing

Well funded after recent divestments

It's all about unlocking the value of our pure trauma business!


aap's

Equity Story

Shareholder Structure (As of 05/04/2017, shareholdings in *aap* \ge 3%)

High degree of stability with a base of long-term oriented investors

- No significant changes for almost 1.5 years*
- Market Cap of approx. EUR 40 million





aap Implantate AG

Lorenzweg 5 • 12099 Berlin • Germany www.aap.de

Fabian Franke

Manager Investor Relations

Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290

E-Mail: ir@aap.de

IR-app:

